Mereo Biopharma Share Discussion Threads

[herb clark] 17/1/2020 16:42

Why has this gone down so much?

[showmethemoneyhoney01] 17/1/2020 06:01

2 analysts recently given (9-1-20) MPH outperform ratings with a 12 month target of 650p and 690p. Link above in Financial Times. Nearly a 20 bagger in 12 months. This was even before the Oncologie Global Licensing Agreement announced on the 13th. Patience needed but rewards could be huge.

[nchanning] 16/1/2020 15:31

Woodford's 8% patient capital stake now managed by Schroder's but the remaining 22% that formed part of his main fund still needs to be sold off. Invesco , another 20% holder, largely from embarrassment and fear of similar liquidity issues , is selling off its stakes in all the blue sky companies that it invested in alongside Woodford . Sadly Invesco will not give a damn about getting Value for long term fund holders , it only carries about the reputational damage of following Woodford into so many illiquid stocks whose price is tanking . They are desperate to get out at any price There will be no sustained rally with 2 such large sellers , any good news can barely affect the share price . When these enormous overhangs clear we may see tremendous rallies in a number of ex- Woodford stocks. Regulators will not want this to drag on

[texaschaser] 15/1/2020 19:24

Iamgreat1 aka @thelongergame aka ZM19 on LSE Aka jammydodger (stopped posting on 6th December set up iamgreat1 on 6th December and ZM19 on LSE 8th December Deramps under one name pumps on other names

[showmethemoneyhoney01] 15/1/2020 10:43

Mereo BioPharma Could Net USD300 Million From Navicixizumab Deal(Alliance News) -

Mereo BioPharma Group PLC shares surged on Monday, after the company sealed a ...
Alliance News13 January, 2020 | 12:24PMEmail Form
(Alliance News) - Mereo BioPharma Group PLC shares surged on Monday, after the company sealed a development & commercialisation licensing agreement with Massachusetts-based Oncologie Inc for the navicixizumab ovarian cancer treatment drug.

Shares in the company climbed 33% to 43.75p in London on Monday.

As part of the agreement, Mereo will receive USD4 million upfront, and in exchange, Oncologie will receive an exclusive worldwide license to develop and commercialise navicixizumab. London-based Mereo could receive another USD2 million, subject to the passing of chemistry, manufacturing & controls milestones, the biopharmaceutical firm said.

What's more, Mereo could be entitled to a further USD300 million related to commercial milestones.

Mereo said: "Oncologie will be responsible for all future research, development and commercialization of navicixizumab. Additionally, Mereo will be eligible to receive up to USD300 million in future clinical, regulatory and commercial milestones, tiered royalties ranging from the mid-single-digit to sub-teen percentages on global annual net sales of navicixizumab, as well as a negotiated percentage of sublicensing revenues from certain sublicensees."

In October, navicixizumab was given fast track designation in the US by the Food & Drug Administration as a treatment for heavily pretreated ovarian cancer.

Mereo acquired navicixizumab in its April merger with OncoMed Pharmaceuticals Inc.

"We believe Oncologie is expertly positioned to further advance navicixizumab through clinical development and towards potential commercialisation.

"While we believe navicixizumab is an exciting oncology asset, we continue to focus our primary efforts on the development of our innovative rare disease portfolio including our lead product candidate setrusumab for the treatment of osteogenesis imperfecta, which continues to advance towards a pivotal phase 3 pediatric study."

In November, Mereo unveiled promising results from a study on setrusumab, a drug for the treatment of bone disease osteogenesis imperfecta. The study met both its primary and secondary endpoints.

By Eric Cunha; [e-mail]

Copyright 2020 Alliance News Limited. All Rights Reserved.

[costax1654x] 15/1/2020 10:17

orm mcap 3 mil,cash 6 mil,no Debts!Plus Gold assets!Distressed Seller due to the sale of tungsten mine(clear our debts and we received 6 mil extra) need shareholders approval

[texaschaser] 14/1/2020 21:04

Iamgreat1 aka @thelongergame aka ZM19 on LSE Aka jammydodger (stopped posting on 6th December set up iamgreat1 on 6th December and ZM19 on LSE 8th December Deramps under one name pumps on other names.

[costax1654x] 14/1/2020 15:50

Distressed seller here!Want out at any price

[leedslad001] 14/1/2020 13:52

https://www.nasdaq.com/market-activity/stocks/mreo/latest-real-time-trades

[leedslad001] 14/1/2020 13:47

MREO up 15% pre market in US

[showmethemoneyhoney01] 14/1/2020 13:16

Some press coverage or decent interview with the CEO would give folks a great overview of where this company is at and it’s potential.

[showmethemoneyhoney01] 14/1/2020 13:10

Target 60p. Broker notes have 12 month target at over 10 times that and that was prior to the last 2 recent RNS’s.

[leedslad001] 14/1/2020 12:38

Somebody is buying them off them on the cheap

[showmethemoneyhoney01] 14/1/2020 12:37

The yanks will be gobbling them up.

[costax1654x] 14/1/2020 12:33

Big chunk for sale!!!

[leedslad001] 14/1/2020 12:29

This will have burnt a few shorters :-)

[showmethemoneyhoney01] 14/1/2020 12:16

2 great 12.00pm RNS on the trot. Market Cap should be a lot higher. Great progress on 2 projects and the share price hardly reacts after dropping down from the 180's 12 months ago.